| Ytd | 4.73% | |
| 1y | -20.10% |
| Open | 1.36 | Prev Close | 0.66 | Low | 1.01 | High | 1.60 | Mkt Cap | 6.51M |
| Vol | 82.47M | Avg Vol | 189.97K | EPS | N/A | P/E | N/A | Forward P/E | 210.67 |
| Beta | 5.00 | Short Ratio | 0.37 | Inst. Own | 5.90% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-10 | 50-d Avg | 0.70 | 200-d Avg | 0.95 | 1yr Est | 19000.00 |
RDHL News
Gainers Redhill Biopharma (NASDAQ:RDHL) shares increased by 96.7% to $1.3 during Monday's pre-m
EIX: -10% | Edison International shares are trading lower following a report suggesting that Califor
Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company'
Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's comme
Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market
Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market
Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market sess
Gainers Can Fite Biopharma (AMEX:CANF) stock moved upwards by 52.0% to $4.52 during Wednesday's
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biop
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opagan
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavir
Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolaviru
RHB-2041 is a next-generation optimized formulation of RedHill's oral RHB-1042, designed for enh
Redhill Biopharma (NASDAQ:RDHL) reported quarterly earnings of $0.00 per share. The company reporte
New preclinical data, independently presented in two posters at the 2026 American Association for Ca
The full sales and operational launch of Talicia, under the joint commercialization agreement betwee
RedHill Biopharma shares fell after a sharp rally as investors took profits, following updates on it
ALT: 24% | Altimmune shares are trading higher after the FDA granted Breakthrough Therapy Designatio
RHB-1021 is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral table
https://ppubs.uspto.gov/api/pdf/downloadPdf/12502381?requestToken=eyJzdWIiOiJiNGI3ZTk4MS0wOTJiLTQyZj
Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbust
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biop
Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori the
The deal aims to accelerate Talicia's entry into new Middle East markets Under the terms of the
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday'
The New York Supreme Court has, on appeal, upheld its original summary judgment ruling in favor of R
Redhill Biopharma (NASDAQ:RDHL) reported $4.079 million in sales this quarter. This is a 58.59 perce
The positive FDA feedback allows for:A novel Phase 2 RHB-204[1] study, planned to be the first ever
Led by Professor Lisa Horvath, from Sydney's Chris O'Brien Lifehouse, and ANZUP, the innovat